Alnylam Pharmaceuticals, Inc.
Angiotensinogen (AGT) iRNA compositions and methods of use thereof

Abstract:

The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the angiotensinogen (AGT) gene, and methods of using such RNAi agents to inhibit expression of AGT and methods of treating subjects having an AGT-associated disorder, e.g., hypertension.